Peptide Comparison
Pancragen vs Crystagen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Pancragen and Crystagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Pancragen | Crystagen | |
|---|---|---|
| Class | Khavinson short peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Metabolic & Weight | Immune |
| Mechanism | Tissue-specific gene expression in pancreatic beta-cells | Tissue-specific gene expression in lymphoid/thymic cells; normalizes T-cell and macrophage activity; doubles HSPA1A heat-shock expression and modulates IL-6 |
| Route | Oral | Oral |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral 1-2 capsules daily for 20-30 day courses |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 8 indexed | 36 indexed |
| Availability | Research | Research |
| Reported risks | Sparse controlled trials | Limited Western evidence; primarily Russian gerontology literature |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Pancragen or Crystagen?
Pancragen and Crystagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Pancragen and Crystagen?
Pancragen is classed as Khavinson short peptide bioregulator; Crystagen is classed as Khavinson short peptide bioregulator. Reported mechanism: Pancragen, Tissue-specific gene expression in pancreatic beta-cells; Crystagen, Tissue-specific gene expression in lymphoid/thymic cells; normalizes T-cell and macrophage activity; doubles HSPA1A heat-shock expression and modulates IL-6. Reported half-life: Pancragen, Short (minutes); Crystagen, Short (minutes). Routes in published studies: Pancragen, Oral; Crystagen, Oral.
Which has stronger evidence, Pancragen or Crystagen?
Pancragen and Crystagen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Pancragen is graded Russian Research, with 2 cited sources on its reference page and 8 indexed studies. Crystagen is graded Russian Research, with 2 cited sources on its reference page and 36 indexed studies.
Which is more accessible, Pancragen or Crystagen?
Neither Pancragen nor Crystagen is an FDA-approved drug. Catalog status: Pancragen, Research; Crystagen, Research.
Are Pancragen and Crystagen ever combined?
Pancragen and Crystagen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…